Brentuximab Vedotin for Systemic Sclerosis

(

BRAVOS

)

ITN Protocol #:

ITN075AI

Branded Name:

BRAVOS

ClinicalTrials.Gov ID:

NCT03222492

Treatment Protocol #:

Therapeutic Area:

Autoimmune Disease

Current Status:

Analysis

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Biostat

ITN Clinical Trial Physician

NIAID Project Manager

Rho Data Manager

PPD Lead Monitor

Study Personnel:

Protocol Chair

Dinesh Khanna khannad@med.umich.edu

Work:

734-763-7182

Protocol Chair

David Fox, MD dfox@umich.edu

Work:

734-936-5566

Protocol Chair

Patti Tosta ptosta@immunetolerance.org

Work:

415-353-4421

Protocol Chair

Karen Chia kchia@immunetolerance.org

Work:

415-353-4290

Protocol Chair

Laura Cooney, PhD lcooney@immunetolerance.org

Work:

734-274-1149

Protocol Chair

Sai Kanaparthi skanaparthi@immunetolerance.org

Work:

(240)235-6101

Protocol Chair

Dawn Smilek, MD PhD dsmilek@immunetolerance.org

Work:

415-353-4308

Protocol Chair

Beverly Welch BWelch@niaid.nih.gov

Work:

(202) 476-5278

Protocol Chair

LaSonia Morgan LaSonia_Morgan@rhoworld.com

Work:

919-595-6379

Protocol Chair

Adrian Lang adrian.lang@ppd.com

Work:

816-674-1404